Navigation Links
ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
Date:9/9/2008

units in the fourth fiscal quarter".

"Our growth in revenues for the quarter," he continued, "was offset at the bottom line by a $1.0 million dollar increase in Research and Development spending year-over-year related to our veterinary stem cell initiative and salary and stock compensation charges for the newly created position Chief Technology Architect. In addition, interest income declined $265,000 versus last year due to decreased cash balances and declining interest rates."

Osgood noted that the Company has achieved several important milestones recently, including receiving a CE-Mark enabling commercial sales of its MarrowXpress(TM), or MXP(TM), in Europe, and authorization from the FDA to initiate commercial sales of the device in the U.S. The MXP is used for concentrating stem cells from bone marrow at both the point-of-care and in a laboratory setting.

"In addition, we have appointed more than a dozen new distributors for our BioArchive System following the restructuring of our agreement with GE Healthcare, giving us distributor relationships in nearly all of our key international markets. Many of these distributors previously sold one or more of our offerings-including the BioArchive-and have established relationships in their markets," Osgood noted.

Osgood said the Company realized a number of key accomplishments in its growth strategy during fiscal 2008, including:

-- Amending its distribution agreement with GE Healthcare and achieving

higher manufacturing output of its AXP bagsets.

-- Developing and receiving regulatory approval of the MXP and initiating

discussions with customers and clinical study investigators.

-- Launching Vantus(TM), Inc., a subsidiary that is a collaboration with

the Center for Equine Health at the University of California, Davis,

that will offer stem cell laboratory services and point-of-care bone

marrow and peripheral blood processi
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 Once ... to provide a larger packaged waste water treatment plant ... King Abdullah Economic City (KAEC). Two years ago Bioshaft ... Jeddah Gate Development, serving two residential towers with an ... is over a quarter million gallons per day and ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/15/2014)... December 15, 2014 METTLER TOLEDO ... PVM tool, ParticleView V19 with PVM technology ... probe-based particle vision and measurement tool continuously captures ... conditions. ParticleView V19 then automatically prepares a report ... particle size and concentration changes. This compelling blend ...
(Date:12/15/2014)... Denmark , Dec. 15, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  This interim analysis consists ... anticipated total enrollment in the study, completing all ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Inc. (Nasdaq: NXXI ), the developer and ... and Diabetes Essentials(R) brands that help consumers manage blood ... chronic joint pain, today announced financial results for the ... 2009.For the quarter the Company reported total revenues of ...
... (Nasdaq: BJGP ) ("BMP Sunstone" or the "Company") ... Healthcare Services,Conference, which will be held at the Waldorf-Astoria in ... Management is currently scheduled to present at 3:30 pm ... same day. , A webcast of ...
... Genesis HealthCare, a provider of long-term care services ... today that Wendy LaBate has been promoted to Senior ... In her new position, LaBate will be responsible for ... Regional Vice Presidents of Operations and Administrators in six ...
Cached Biology Technology:Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 2Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 3Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 4Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 5Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 6Nutrition 21 Announces Second Consecutive Profitable Quarter in Q2 Fiscal 2009 7BMP Sunstone to Present at UBS Global Healthcare Services Conference 2Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 4, 2014  Tute Genomics, a leader in cloud-based ... Series A1 funding led by UK-based Eurovestech. Peak Ventures ... the investment round. "We are at a ... next-generation sequencing and seeks new approaches for the diagnosis, ... , MD MBA, and CEO of Tute Genomics. "One ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... they develop, vertebrate embryos form vertebrae in a ... that this process of body segmentation is controlled ... oscillating activity of certain genes within embryonic cells. ... timing system works. A new international ...
... Ind. -- Scientists at Indiana University and international collaborators ... a single molecule, producing a more effective therapy with ... obesity and related medical conditions. , The studies were ... Standiford H. Cox Distinguished Professor of Chemistry and the ...
... A new study demonstrates the dynamic role cilia play ... brain. Cilia are tiny hair-like structures on the surfaces ... radio antennae. In developing mouse embryos, researchers were ... migrate. The cilia appear to be receiving signals needed ...
Cached Biology News:Study sheds light on genetic 'clock' in embryonic cells 2Hormone combination effective and safe for treating obesity in mice 2Cilia guide neuronal migration in developing brain 2
Pronase Reagent...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Antigen peptide transporter ... TAP2) (Peptide transporter PSF2) ... (PSF-2) (Peptide transporter involved ... [Source:Uniprot/SWISSPROT;Acc:Q03519] ...
Biology Products: